NLRP3 Recombinant Protein: Dual-Signal Mechanism of Inflammasome Activation and Regulatory Hub of the Tumor Microenvironment

Author: Senior Product Manager of UA Views：8

This article focuses on the molecular characteristics and activation mechanisms of the NLRP3 inflammasome, systematically elaborating the role of the two-signal model (priming signal and activation signal) in NLRP3 inflammasome assembly and the maturation and secretion of IL-1β/IL-18, analyzing the differential regulation of phagocyte fate by different activation triggers and its impact on antitumor immunity, and exploring the pro-tumor mechanisms by which NLRP3 mediates angiogenesis, immunosuppression, and metastasis in the tumor microenvironment, as well as its tissue-specific exceptions.

Recent Advances
Product Information

Recent Advances

NLRP3 Recombinant Protein: The Dual-Signal Mechanism of Inflammasome Activation and a Regulatory Hub in the Tumor Microenvironment

Summary: This article focuses on the molecular characteristics and activation mechanisms of the NLRP3 inflammasome, systematically elaborating the role of the priming signal and activation signal dual-signal model in NLRP3 inflammasome assembly and the maturation and secretion of IL-1β/IL-18, analyzing the differential regulation of phagocyte fate by different activation triggers and its impact on antitumor immunity, and discussing the pro-tumor mechanisms by which NLRP3 mediates angiogenesis, immunosuppression, and metastasis in the tumor microenvironment, as well as its tissue-specific exceptions.

I. The Dual-Signal Model of NLRP3 Inflammasome Activation and Molecular Assembly.

Activation of the NLRP3 inflammasome follows the classical dual-signal model. In the priming signal stage, the binding of pathogen-associated molecular patterns or damage-associated molecular patterns to Toll-like receptors or cytokine receptors, together with their respective cytokines such as IL-1α, IL-1β, or TNFα, leads to NF-κB-mediated gene expression upregulation of inflammasome components, elevating the transcriptional levels of NLRP3 and pro-IL-1β. In the activation signal stage, activation occurs through pathogen-associated molecular patterns or damage-associated molecular patterns, which activate upstream signals leading to NLRP3 self-oligomerization. NLRP3 then interacts with ASC, pro-caspase-1 is recruited, leading to caspase-1 activation, and activated caspase-1 then cleaves pro-IL-1β and pro-IL-18. The biologically active IL-1β and IL-18 are subsequently secreted into the extracellular space. This four-step cascade of “transcriptional priming—assembly activation—substrate cleavage—mature secretion” constitutes the core framework through which the NLRP3 inflammasome exerts its functions.

II. Differential Regulation of Phagocyte Fate by Different Activation Signals.

After recognition of damage-associated molecular patterns or pathogen-associated molecular patterns, NF-κB translocation in the nucleus of macrophages such as dendritic cells mediates the transcription of NLRP3 and pro-IL-1. Next, the inflammasome trigger, i.e., signal 2, will induce the formation of the NLRP3 inflammasome. Depending on the nature of signal 2, cells may undergo different fates. For example, triggers such as oxidized phospholipids lead to NLRP3 inflammasome formation and highly active dendritic cells. Highly active dendritic cells remain viable and are able to induce durable and effective adaptive antitumor responses while releasing IL-1 and other cytokines such as IL-12 and IL-23. On the other hand, triggers such as ATP lead to NLRP3 inflammasome formation and GSDM-mediated cell death, failing to induce effective antitumor immunity. This finding has important immunotherapeutic implications——activating NLRP3 in the same way, depending on the triggering signal, leads to two completely different outcomes: “viable highly active antigen-presenting cells” versus “pyroptotic cell death,” suggesting that therapeutic strategy design should focus on the nature of the activation signal rather than activation alone.

III. Cell-Intrinsic Mechanisms of NLRP3 Activation in the Tumor Microenvironment.

In the tumor microenvironment, the mechanisms of NLRP3 activation can be divided into two categories: tumor cell-intrinsic mechanisms and host cell-intrinsic mechanisms. Abnormal activation of NLRP3 within the tumor microenvironment leads to increased secretion of IL-1β and IL-18. Dysregulation of these cytokines leads to tumor-promoting mechanisms such as angiogenesis, immunosuppression, and metastasis. Therefore, NLRP3 activation represents a key immune checkpoint within the tumor microenvironment, acting as a master switch of inflammation-mediated tumor progression. The positioning of this “master switch” means that NLRP3 is not merely a passive inflammatory marker but an active functional hub regulating the direction of the tumor microenvironment.

IV. Tissue Specificity and Exceptional Cases of the Pro-Tumor Effects of NLRP3.

In this review, the researchers described NLRP3 activation in cancer. Some activation mechanisms are intrinsic to the tumor microenvironment, while others depend on environmental stimuli or therapeutic interventions. Regardless of the mechanism of NLRP3 activation, a situation emerges in which unchecked inflammasome formation is generally associated with tumor progression. Some preclinical studies focus on constitutively activated NLRP3 in tumor cells, as in the case of metastatic melanoma cells, while other cancer preclinical models focus on the paracrine effects of tumor cells, as in the cases of breast cancer and pancreatic cancer. Regardless of origin, tumor cells utilize NLRP3 activation to induce inflammatory responses, promoting immunosuppression, angiogenesis, and immune evasion, ultimately producing a tumor-permissive environment.

However, the pro-tumor role of NLRP3 in cancer is exceptional. For example, in colorectal cancer, NLRP3 activation appears to enhance the immune system and limit tumor progression. Another exception is “hyperactivated” dendritic cells, in which NLRP3 activation leads to IL-1β production independent of pyroptosis. In summary, the role of NLRP3 in cancer appears to be tissue- and cancer-specific, which requires clarification of NLRP3 targeting. This conclusion suggests that when targeting NLRP3 as a therapeutic target, it must be evaluated in the context of specific cancer types and microenvironmental backgrounds, rather than adopting a one-size-fits-all intervention strategy.

V. Conclusion.

In NLRP3-related basic research and inflammasome-targeted drug development, high-quality recombinant NLRP3 protein is a core tool for dissecting its self-oligomerization mechanism, interaction with ASC, and inhibitor binding activity. The His-StrepII dual tag facilitates efficient purification via immobilized metal affinity chromatography and Strep-Tactin affinity chromatography, and enables detection and capture via anti-tag antibodies. To meet the needs of NLRP3 functional research and exploration of inflammasome regulatory mechanisms, UIA provides NLRP3 His-StrepII Tag Protein, Human. This product is suitable for applications such as in vitro studies of NLRP3 self-oligomerization and inflammasome assembly mechanisms, analysis of NLRP3 interactions with ASC and pro-caspase-1, evaluation and screening of the binding activity of NLRP3 inflammasome inhibitors, and exploration of the mechanisms of NLRP3-mediated inflammatory responses in the tumor microenvironment.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next